SUPPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 RELEASE FROM HUMAN CEREBRAL ENDOTHELIUM BY PLASMINOGEN ACTIVATORS - A FACTOR POTENTIALLY PREDISPOSING TO INTRACRANIAL BLEEDING
Ma. Shatos et al., SUPPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 RELEASE FROM HUMAN CEREBRAL ENDOTHELIUM BY PLASMINOGEN ACTIVATORS - A FACTOR POTENTIALLY PREDISPOSING TO INTRACRANIAL BLEEDING, Circulation, 94(4), 1996, pp. 636-642
Background Intracranial bleeding is the most catastrophic potential co
mplication of treatment with thrombolytic agents. To identify potentia
l factors that may contribute to this problem, we characterized elabor
ation by human brain endothelial cells of plasminogen activator inhibi
tor-1 (PAI-1) and measured PAI-1 mRNA levels. Methods and Results When
human cerebral microvascular endothelial cells (HCMEC), pial arterial
endothelial cells, and middle meningeal arterial endothelial cells we
re exposed to 10 to 1000 ng/mL recombinant tissue-type plasminogen act
ivator (RTPA), urokinase-type plasminogen activator (UPA), or streptok
inase/plasminogen (37 U streptokinase plus 2 mu mol/L plasminogen) for
24 hours, they exhibited concentration-dependent decreases in elabora
tion of PAI-1 of 65+/-3%, 48+/-3%, and 59+/-8%. UPA and streptokinase/
plasminogen elicited decreases of 33+/-8% and 35+/-4%, respectively, t
hat were specific with respect to the protease agonists as to total pr
otein synthesis and cell type; ie, neither human umbilical vein endoth
elial cells nor cerebral pericytes exhibited inhibition of PAI-1 elabo
ration. No decrease in HCMEC PAI-I elaboration was induced by coagulat
ion factor Xa (10 nmol/L). A 2.7+/-0.5-fold increase was induced by cu
-thrombin (10 nmol/L). PAI-I secretion from HCMEC decreased within 4 h
ours of exposure to 100 ng/mL RTPA. In HCMEC exposed to RTPA for 8 hou
rs, PAI-1 mRNA decreased from 176+/-20 to 43+/-2.2 pg/mu g RNA. Conclu
sions These results indicate that brain endothelial cells exposed to R
TPA exhibit paradoxically diminished elaboration of PAI-1. This proper
ty may render brain vasculature vulnerable to attack by serine proteas
es, thereby predisposing to injury and initiating an underlying subseq
uent intracerebral hemorrhage in patients given plasminogen activators
for treatment of coronary thrombosis.